FindTrial
Sign In

Role of Lactoferrin in Anemia in Chronic Kidney Disease

Lactoferrin With Iron Versus Iron In treatment of Anemia In Chronic Kidney Disease: A Randomized Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/04/024746
Enrollment
65
Registered
2020-04-20
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N189- Chronic kidney disease, unspecified

Interventions

Intervention1: Intervention 1: Lactoferrin 100 mg Twice daily for one month: oral tablet twice a day Control Intervention1: standard chronic kidney disease care: standard chronic kidney disease care

Sponsors

POST GRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH CHANDIGARH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: CKD (eGFR Age >18years Hb TSAT

Exclusion criteria

Exclusion criteria: Hematological malignancy Primary hematological diseases causing anemia Ongoing infection Hepatitis B, C or HIV Systemic immunosuppressive therapy Pregnancy/ lactation

Design outcomes

Primary

MeasureTime frame
Treatment response-Hb levelsTimepoint: baseline, one month—

Secondary

MeasureTime frame
iron profile parameters (Serum iron, TSAT, TIBC, Ferriton), Serum hepcidin and IL6 levels, ESR, CRP, Lipid profile, 2D Echo, h/o infection episodes, hospitalization, requirement of blood transfusion, erythropoietin use and required dosagesTimepoint: 1 month—

Countries

India

Contacts

Public ContactDr Smita Divyaveer

Post Graduate Institute of Medical Education and Research, Chandigarh

smitadivyaveer@gmail.com8017062986

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026